Cliff Asness's VRTX Position Overview
Cliff Asness (via Aqr Capital Management LLC) currently holds 143,651 shares of Vertex Pharmaceuticals Incorporated (VRTX) worth $65.13 M, representing 0.03% of the portfolio. First purchased in 2012-Q4, this long-term strategic position has been held for 51 quarters.
Based on 13F filings since 2013, Cliff Asness has maintained a long-term strategic position in VRTX, representing a significant commitment to this investment thesis. Largest addition occurred in Q3 2017, adding 1.05 M shares. Largest reduction occurred in Q4 2018, reducing 522,311 shares.
Analysis based on 13F filings available since 2013 Q2
Cliff Asness's Vertex Pharmaceuticals Incorporated (VRTX) Holding Value Over Time
Track share changes against reported price movement
Quarterly Vertex Pharmaceuticals Incorporated (VRTX) Trades by Cliff Asness
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | -18,032 | Reduce 11.15% | 143,651 | $453.36 |
| Q3 2025 | +20,147 | Add 14.23% | 161,683 | $391.64 |
| Q2 2025 | -4,335 | Reduce 2.97% | 141,536 | $439.71 |
| Q1 2025 | -99,914 | Reduce 40.65% | 145,871 | $477.34 |
| Q4 2024 | -235,076 | Reduce 48.89% | 245,785 | $402.70 |
| Q3 2024 | -55,253 | Reduce 10.31% | 480,861 | $464.00 |
| Q2 2024 | -130,577 | Reduce 19.59% | 536,114 | $468.72 |
| Q1 2024 | +21,923 | Add 3.40% | 666,691 | $418.01 |
| Q4 2023 | +1,271 | Add 0.20% | 644,768 | $406.89 |
| Q3 2023 | +31,067 | Add 5.07% | 643,497 | $347.74 |
| Q2 2023 | +40,915 | Add 7.16% | 612,430 | $351.91 |
| Q1 2023 | -16,079 | Reduce 2.74% | 571,515 | $315.04 |
| Q4 2022 | +93,063 | Add 18.82% | 587,594 | $286.82 |
| Q3 2022 | -22,253 | Reduce 4.31% | 494,531 | $289.54 |
| Q2 2022 | +16,840 | Add 3.37% | 516,784 | $278.41 |
| Q1 2022 | -98,539 | Reduce 16.46% | 499,944 | $257.89 |
| Q4 2021 | -40,834 | Reduce 6.39% | 598,483 | $219.60 |
| Q3 2021 | -67,436 | Reduce 9.54% | 639,317 | $181.39 |
| Q2 2021 | -203,774 | Reduce 22.38% | 706,753 | $197.09 |
| Q1 2021 | +350,146 | Add 62.48% | 910,527 | $214.41 |
| Q4 2020 | -83,887 | Reduce 13.02% | 560,381 | $230.39 |
| Q3 2020 | +32,453 | Add 5.30% | 644,268 | $271.59 |
| Q2 2020 | +16,945 | Add 2.85% | 611,815 | $287.17 |
| Q1 2020 | +184,560 | Add 44.98% | 594,870 | $232.13 |
| Q4 2019 | +138,186 | Add 50.78% | 410,310 | $218.43 |
| Q3 2019 | +22,158 | Add 8.86% | 272,124 | $168.22 |
| Q2 2019 | -194,184 | Reduce 43.72% | 249,966 | $180.20 |
| Q1 2019 | -314,883 | Reduce 41.48% | 444,150 | $182.29 |
| Q4 2018 | -522,311 | Reduce 40.76% | 759,033 | $165.71 |
| Q3 2018 | +449,549 | Add 54.05% | 1.28 M | $192.74 |
| Q2 2018 | -432,617 | Reduce 34.21% | 831,795 | $169.96 |
| Q1 2018 | -253,423 | Reduce 16.70% | 1.26 M | $162.98 |
| Q4 2017 | -372,855 | Reduce 19.72% | 1.52 M | $149.86 |
| Q3 2017 | +1.05 M | Add 124.05% | 1.89 M | $152.04 |
| Q2 2017 | +601,942 | Add 248.80% | 843,884 | $128.87 |
| Q1 2017 | +124,781 | Add 106.50% | 241,942 | $109.35 |
| Q4 2016 | +117,161 | New Buy | 117,161 | $73.67 |
| Q1 2016 | -46,414 | Sold Out | 0 | $0.00 |
| Q4 2015 | -426,800 | Reduce 90.19% | 46,414 | $125.82 |
| Q3 2015 | -348,218 | Reduce 42.39% | 473,214 | $104.14 |
| Q2 2015 | -81,323 | Reduce 9.01% | 821,432 | $123.48 |
| Q1 2015 | +275,353 | Add 43.89% | 902,755 | $117.97 |
| Q4 2014 | -42,374 | Reduce 6.33% | 627,402 | $118.80 |
| Q3 2014 | +185,598 | Add 38.33% | 669,776 | $112.31 |
| Q2 2014 | +29,200 | Add 6.42% | 484,178 | $94.68 |
| Q1 2014 | -65,901 | Reduce 12.65% | 454,978 | $70.72 |
| Q4 2013 | +80,216 | Add 18.20% | 520,879 | $74.30 |
| Q3 2013 | -71,882 | Reduce 14.02% | 440,663 | $75.82 |
| Q2 2013 | +512,545 | Add 0.00% | 512,545 | $79.87 |
| Q4 2012 | +966,805 | Add 0.00% | 966,805 | $41.94 |
Cliff Asness's Vertex Pharmaceuticals Incorporated Investment FAQs
Cliff Asness first purchased Vertex Pharmaceuticals Incorporated (VRTX) in Q4 2012, acquiring 966,805 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness has held Vertex Pharmaceuticals Incorporated (VRTX) for 51 quarters since Q4 2012.
Cliff Asness's largest addition to Vertex Pharmaceuticals Incorporated (VRTX) was in Q3 2017, adding 1,890,690 shares worth $287.46 M.
According to the latest 13F filing for Q4 2025, Cliff Asness's firm, Aqr Capital Management LLC, owns 143,651 shares of Vertex Pharmaceuticals Incorporated (VRTX), valued at approximately $65.13 M.
As of the Q4 2025 filing, Vertex Pharmaceuticals Incorporated (VRTX) represents approximately 0.03% of Cliff Asness's publicly disclosed stock portfolio, making it one of their key holdings.
Cliff Asness's peak holding in Vertex Pharmaceuticals Incorporated (VRTX) was 1,890,690 shares, as reported at the end of Q3 2017.